A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (PRISMS)

• ClinicalTrials.gov Identifier: NCT02072226
• Recruitment Status: Terminated
• First Posted: February 26, 2014
• Results First Posted: July 3, 2018
• Last Update Posted: July 3, 2018
• Sponsor: Genentech, Inc.
• Information provided by (Responsible Party): Genentech, Inc.

Tracking Information

• First Submitted Date: February 24, 2014
• First Posted Date: February 26, 2014
• Results First Submitted Date: March 7, 2018
• Results First Posted Date: July 3, 2018
• Last Update Posted Date: July 3, 2018
• Actual Study Start Date: May 31, 2014
• Actual Primary Completion Date: March 22, 2017 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: June 4, 2018)

Percentage of Participants With a Modified Rankin Scale (mRS) Score of 0 or 1 at Day 90 [ Time Frame: Day 90 ]

mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS.

• Original Primary Outcome Measures (submitted: February 24, 2014): Proportion of patients with a modified Rankin Scale (mRS) score of 0 or 1 [ Time Frame: Assessed at Day 90 ]

Current Secondary Outcome Measures (submitted: June 4, 2018)

• Distribution of Participants Across the Ordinal mRS [ Time Frame: Day 90 ]
  mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS.
• Percentage of Participants With Global Favorable Recovery on mRS, NIHSS, BI, and GOS [ Time Frame: Day 90 ]
  Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index [BI] greater than or equal to 95, and Glasgow Outcome Scale [GOS] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales.
• Percentage of Participants With Symptomatic Intracranial Hemorrhage (ICH ) [ Time Frame: Within 36 hours after study drug administration on Day 1 ]
  ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration.
• Percentage of Participants With Any ICH [ Time Frame: Within 36 hours after study drug administration on Day 1 ]
  To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration.
• Overall Mortality [ Time Frame: From baseline to Day 90 ]
  Reported here is the percentage of participants who died due to any cause during the study.
• Percentage of Participants Who Died Due to Stroke and Neurological Disorders [ Time Frame: From baseline to Day 90 ]
  Reported here is the percentage of participants who died due to stroke and neurological disorders.
• Percentage of Participants With Adverse Events [ Time Frame: From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90. ]
  An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
• Percentage of Participants With Serious Adverse Events [ Time Frame: From baseline to Day 90 ]
  A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.

Original Secondary Outcome Measures (submitted: February 24, 2014)

• Change in NIH Stroke Scale (NIHSS) score [ Time Frame: 90 days ]
• Measure of daily functioning (Barthel Index score) at end of study [ Time Frame: Day 90 ]
• Assessment of disability due to brain injury using Glasgow Outcome Scale [ Time Frame: Day 90 ]
• Incidence of symptomatic intracranial hemmorhage or any intracranial hemorrhage [ Time Frame: 36 hours ]
• Overall mortality [ Time Frame: 90 days ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
• Official Title: A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)
• Brief Summary: PRISMS is a double-blind, multicenter, randomized, Phase IIIb study to evaluate the efficacy and safety of intravenous (IV) alteplase in participants with mild acute ischemic strokes that do not appear to be clearly disabling. Participants will be randomized in a 1:1 ratio to receive within 3 hours of last known well time either 1) one dose of IV alteplase and one dose of oral aspirin placebo or 2) one dose of IV alteplase placebo and one dose of oral aspirin 325 milligrams (mg).
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Treatment
• Condition: Stroke

Intervention

• Drug: Alteplase
  Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
  Other Name: Activase; RO5532960
• Drug: Alteplase Placebo
  Single dose of alteplase placebo will be administered as IV injection.
• Drug: Aspirin
  Single dose of aspirin will be administered at 325 mg orally.
• Drug: Aspirin Placebo
  Single dose of aspirin placebo will be administered orally.

Study Arms

• Active Comparator: Alteplase Placebo + Aspirin
  Participants will receive single dose of IV alteplase placebo and aspirin orally.
  Interventions:

  • Drug: Alteplase Placebo
  • Drug: Aspirin
• Experimental: Alteplase + Aspirin Placebo
  Participants will receive single dose of IV alteplase and aspirin placebo orally.
  Interventions:

  • Drug: Alteplase
  • Drug: Aspirin Placebo

Publications *

• Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, Broderick J, Chatterjee A, Jauch EC, Levine SR, Romano JG, Saver JL, Vagal A, Purdon B, Devenport J, Pavlov A, Yeatts SD; PRISMS Investigators. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018 Jul 10;320(2):156-166. doi: 10.1001/jama.2018.8496.
• Zhao W, Mu Y, Tayama D, Yeatts SD. Comparison of statistical and operational properties of subject randomization procedures for large multicenter clinical trial treating medical emergencies. Contemp Clin Trials. 2015 Mar;41:211-8. doi: 10.1016/j.cct.2015.01.013. Epub 2015 Jan 29.
• Choi JC, Jang MU, Kang K, Park JM, Ko Y, Lee SJ, Cha JK, Kim DH, Park SS, Park TH, Lee KB, Lee J, Kim JT, Cho KH, Yu KH, Oh MS, Lee BC, Cho YJ, Kim DE, Lee JS, Lee J, Gorelick PB, Bae HJ. Comparative effectiveness of standard care with IV thrombolysis versus without IV thrombolysis for mild ischemic stroke. J Am Heart Assoc. 2015 Jan 27;4(1):e001306. doi: 10.1161/JAHA.114.000596.

Recruitment Information

• Recruitment Status: Terminated
• Actual Enrollment (submitted: February 20, 2017): 313
• Original Estimated Enrollment (submitted: February 24, 2014): 948
• Actual Study Completion Date: March 22, 2017
• Actual Primary Completion Date: March 22, 2017 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Mild ischemic stroke defined as the most recent pre-treatment NIHSS score of less than or equal to(</=) 5 and determined as not clearly disabling by the investigator
• Study treatment initiated within 3 hours of last time participant seen normal

Exclusion Criteria:

• Computed tomography (CT) or magnetic resonance imaging (MRI) findings of one of the following:

  1. CT with clear large hypodensity that is greater than (>) one-third middle cerebral artery (MCA) territory (or >100 cubic centimeter [cc] if not in MCA territory)
  2. MRI with clear large hyperintensity on concurrent diffusion-weighted (DW) and fluid-attenuated inversion recovery (FLAIR) that is greater than one-third MCA territory (or greater than 100 cc if not in MCA territory),
  3. Imaging lesion consistent with acute hemorrhage, or
  4. Evidence of intraparenchymal tumor
• Disability prior to the presenting stroke

• Standard contraindications to IV alteplase within 3 hours of symptom onset, including:

  1. Head trauma, myocardial infarction, or previous stroke within the previous 3 months
  2. Gastrointestinal or urinary tract hemorrhage within the previous 21 days
  3. Major surgery within the previous 14 days
  4. Arterial puncture at non-compressible site within the previous 7 days
  5. Any history of ICH with the exception of those less than (<) 5 chronic microbleeds on MRI
  6. Elevated blood pressure defined by systolic blood pressure >185 millimeters of mercury (mm Hg) or diastolic blood pressure >110 mm Hg, or treatments requiring aggressive measures to achieve acceptable levels
  7. Treatment with unfractioned heparin within past 48 hours and activated partial thromboplastin time outside normal range
  8. Blood glucose <50 milligrams per deciliter (mg/dL)
  9. International normalized ratio >1.7
  10. Platelet count <100,000 per cubic millimeter (/mm^3)
  11. Treatment with a direct thrombin inhibitor (dabigatran) or a factor Xa inhibitor (apixaban, rivaroxaban, edoxaban) within the last 48 hours
• Allergic reaction to study drug, aspirin, or nonsteroidal anti-inflammatory drugs (NSAIDs)
• Females of childbearing age who are known to be pregnant and/or lactating
• Inability to swallow, which would prevent oral intake of aspirin or aspirin placebo tablet
• Other serious, advanced, or terminal illness that would confound the clinical outcome at 90 days
• Current or recent (within 3 months) participation in another investigational drug treatment protocol
• Anticipated inability to obtain 3-month follow-up assessments
• Previous enrollment in PRISMS
• Any other condition deemed by the investigator that would pose hazard to the participant with alteplase treatment

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT02072226
• Other Study ID Numbers: ML29093
• Has Data Monitoring Committee: Not Provided

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Genentech, Inc.
• Original Responsible Party: Same as current
• Current Study Sponsor: Genentech, Inc.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Clinical Trials; Genentech, Inc.

• PRS Account: Genentech, Inc.
• Verification Date: June 2018